Results 11 to 20 of about 688 (142)

Ospemifene May Not Treat Vulvar Atrophy: A Report of Two Cases [PDF]

Sexual Medicine, 2016
Introduction: Ospemifene (Osphena, Shionogi Inc, Florham, NJ, USA) is an estrogen agonist and antagonist approved by the U.S. Federal Drug Administration for the treatment of “moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due ...
Andrew T. Goldstein, MD, Michelle A. King, MSC   +1 more
doaj   +2 more sources

Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause

Clinical Interventions in Aging, 2014
Gregory T Wurz, Chiao-Jung Kao, Michael W DeGregorio Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis, Sacramento, CA, USA Abstract: During the menopausal transition, women experience a number of ...
Wurz GT, Kao CJ, DeGregorio MW
doaj   +1 more source

Improvements to the Vulva, Vestibule, Urethral Meatus, and Vagina in Women Treated With Ospemifene for Moderate to Severe Dyspareunia: A Prospective Vulvoscopic Pilot Study

Sexual Medicine, 2018
Introduction: Ospemifene, an oral selective estrogen receptor modulator approved for the treatment of mild to moderate dyspareunia from menopause, has been shown to moderate sexual pain and vaginal epithelial cell characteristics. However, no prospective
Sue W. Goldstein, BA, CCRC, CSE, IF, Ashley G. Winter, MD, Irwin Goldstein, MD, IF   +2 more
doaj   +3 more sources

Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy [PDF]

International Journal of Women's Health, 2016
Santiago Palacios,1 María Jesús Cancelo2 1Palacios Institute of Women’s Health, Madrid, Spain; 2Gynecology and Obstetrics Department, Guadalajara University Hospital, University of Alcalá, Spain Abstract: The physiological ...
Palacios S, Cancelo MJ
doaj   +1 more source

Ospemifene in the Management of Vulvar and Vaginal Atrophy: Focus on the Assessment of Patient Acceptability and Ease of Use [PDF]

Patient Preference and Adherence, 2020
Angelo Cagnacci, 1 Anjeza Xholli, 2 Martina Venier 2 1Obstetrics and Gynaecology Unit, Obstetrics and Gynaecology University of Genova, Genova, Italy; 2Obstetrics and Gynaecology Unit, Azienda Sanitaria Universitaria Integrata di Udine, Udine ...
Cagnacci A, Xholli A, Venier M
doaj   +2 more sources

Vaginal Laser Treatment for Genitourinary Syndrome of the Menopause: A Dose-Determining Study in Breast Cancer Survivors. [PDF]

Lasers Surg Med
ABSTRACT Objectives Breast cancer survivors (BCSs) receiving endocrine therapy frequently develop genitourinary syndrome of menopause, characterized by vaginal dryness, pain, and urinary symptoms. Fractional CO2 vaginal laser therapy has been proposed as a non‐hormonal management option, but the optimal number of treatment sessions remains unclear.
Jacobsen S, Glavind-Kristensen M, Jensen AB, Forman A, Bertelsen VM, Bor P.   +5 more
europepmc   +2 more sources

Care after premenopausal risk‐reducing salpingo‐oophorectomy in high‐risk women: Scoping review and international consensus recommendations

BJOG: An International Journal of Obstetrics &Gynaecology, Volume 130, Issue 12, Page 1437-1450, November 2023., 2023
Abstract Women at high inherited risk of ovarian cancer are offered risk‐reducing salpingo‐oophorectomy (RRSO) from age 35 to 45 years. Although potentially life‐saving, RRSO may induce symptoms that negatively affect quality of life and impair long‐term health. Clinical care following RRSO is often suboptimal.
Denise R. Nebgen, Susan M. Domchek, Joanne Kotsopoulos, Joanne A. de Hullu, Emma J. Crosbie, Vincent Singh Paramanandam, Monique M.A. Brood ‐ van Zanten, Barbara M. Norquist, Theresa Guise, Serge Rozenberg, Allison W. Kurian, Holly J. Pederson, Nese Yuksel, Rachel Michaelson‐Cohen, Sharon L. Bober, Agnaldo Lopes da Silva Filho, Nora Johansen, F. Guidozzi, D. Gareth Evans, Usha Menon, Sheryl A. Kingsberg, C. Bethan Powell, Giovanni Grandi, Claudia Marchetti, Michelle Jacobson, Donal J. Brennan, Martha Hickey   +26 more
wiley   +1 more source

Efficacy of Hormonal and Nonhormonal Approaches to Vaginal Atrophy and Sexual Dysfunctions in Postmenopausal Women: A Systematic Review [PDF]

Revista Brasileira de Ginecologia e Obstetrícia, 2023
Objective To evaluate the efficacy of the hormonal and nonhormonal approaches to symptoms of sexual dysfunction and vaginal atrophy in postmenopausal women.
Ayane Cristine Alves Sarmento, Ana Paula Ferreira Costa, Juliana Lírio, José Eleutério Jr, Pedro Vieira Baptista, Ana Katherine Gonçalves   +5 more
doaj   +1 more source

Experience with ospemifene in patients with vulvar and vaginal atrophy: case studies with bone marker profiles

Drugs in Context, 2020
Selective estrogen receptor modulators (SERMs) exhibit varying agonist/antagonist activities on estrogen receptors in tissues, although most SERMs, including ospemifene, have agonist effects on bone.
María del Carmen Pingarrón Santofimia, Silvia Pilar González Rodríguez, Mariella Lilue, Santiago Palacios   +3 more
doaj   +1 more source

Treatment of vulvar pain caused by atrophy: a systematic review of clinical studies

Clinical and Experimental Obstetrics & Gynecology, 2021
Background: The signs and symptoms of the genitourinary syndrome of menopause are well established, and there is extensive knowledge with high scientific evidence about the response that vaginal and urinary tissues present to various treatments. However,
Sonia Sánchez, Laura Baquedano, Nicolás Mendoza   +2 more
doaj   +1 more source